EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Neola Medical AB (NEOLA) fair value: what the stock is really worth

As of Oct 14, 2026: fair value of Neola Medical AB SEK 0.13, price SEK 0.47, upside -72.2%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0014829255

NM Thin data Oct 3, 2026

Neola Medical AB

NEOLA · ST

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 72% below what the stock costs today.

Quality 47/100
Mixed Growth (revenue 3y +2.8 %/yr in SEK)
Fair value kr 0.1300 · Strongly overvalued (−72.2%)
Negative free cash flow
Trails peers (2/7)
Narrow moat 8/100 · thin data
Thin data
Watch Neola Medical AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 3.71 kr 0.4540 Fair Value kr 0.1300 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 0.4540 – kr 3.71 · fair‑value band kr 0.0900 – kr 0.1600 · the kr 0.4680 price screens above the kr 0.1300 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Neola Medical in your weekly email

Every Wednesday you see whether Neola Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden.

Show moreShow less

It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration.

The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.

Stock analysis

Neola Medical AB (NEOLA) currently trades at kr 0.4680, while our model-based Fair Value estimate is kr 0.1300, 72.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.0900 (bear) to kr 0.1600 (bull), the price of kr 0.4680 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Neola Medical AB reported revenue of 0 SEK in FY2025 versus 625K SEK in FY2021. Reported net income was −11.0M SEK in FY2025.

Key figures

Market cap 54.1M SEK (≈ $5.4M) · EPS (TTM) kr −0.1600 · Return on equity −14.2% · Return on assets (EBIT) −14.2% · Operating margin −111% · Revenue (TTM) 38.0K SEK · Revenue growth (YoY) +52.2% · Free cash flow −12.0M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −72%, NEOLA screens richer than that median.

Fair Value models

Bear kr 0.0900 Fair Value kr 0.1300 Bull kr 0.1600
Price kr 0.4680 · Upside -72.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.3400 kr 0.4600 kr 0.6900 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.3400 kr 0.4600 kr 0.6900 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 39
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Momentum 3
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 32
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,916.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−220.3% (2018) → −1,177.0% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NEOLA screens overvalued: fair value 72% below the price. Compare with Abbott Laboratories, →

Compare Neola Medical AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 329 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −72.2% · Bottom 25%
Profitability
Return on assets −14.0% · Bottom 25%
Operating margin (12 months) −111.1% · Bottom 25%
Growth and dividend
Revenue growth 52.2% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.07× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 7
FUTURE (revenue growth)100 · sector 35
PAST (return on equity)0 · sector 16
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $282.60 $310.86 +10% vs NEOLA
Boston Scientific Corporation BSX $42.19 $46.41 +10% vs NEOLA
DexCom, Inc DXCM $84.11 $92.52 +10% vs NEOLA
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥166.00 ¥182.60 +10% vs NEOLA
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs NEOLA
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs NEOLA
Siemens Healthineers AG SHL €38.26 €35.19 −8% vs NEOLA
Abbott Laboratories, ABT $102.61 $74.79 −27% vs NEOLA
Medtronic plc MDT $91.93 $65.61 −29% vs NEOLA
Koninklijke Philips N.V PHIA €22.18 €15.23 −31% vs NEOLA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neola Medical AB · Fair Value
kr 0.1300 −72%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Neola Medical AB Fair Value". https://www.fairvalue-calculator.com/stock/NEOLA

Frequently asked questions

Is Neola Medical AB (NEOLA) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 0.1300 versus a price of kr 0.4680, about −72% upside (overvalued).
What is the fair value of NEOLA?
Our model-based fair value for Neola Medical AB is kr 0.1300 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 0.4680.
What is the quality score of NEOLA?
Neola Medical AB has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neola Medical AB (NEOLA)?
Our model-based price target is the fair value of kr 0.1300 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 0.0900, optimistic scenario kr 0.1600. It is a calculation from audited fundamentals, not an analyst target.
What is the Neola Medical AB stock forecast for 2026?
Our models put fair value at kr 0.1300, about −72% upside versus a price of kr 0.4680 (overvalued). Cautious scenario kr 0.0900, optimistic scenario kr 0.1600. The calculation is refreshed regularly with new filings.
What is the revenue of Neola Medical AB (NEOLA)?
Neola Medical AB reported trailing-twelve-month revenue of about 38.0K SEK (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Neola Medical AB (NEOLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neola Medical AB it is kr 0.1300 per share (as of Oct 3, 2026), against a price of kr 0.4680. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Neola Medical AB stock overvalued or undervalued in 2026?
As of Oct 3, 2026, NEOLA trades above its calculated fair value: price kr 0.4680, fair value kr 0.1300, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEOLA?
No. The price is what the market pays today (kr 0.4680); the fair value is what the company's own numbers justify (kr 0.1300). For Neola Medical AB the two are kr 0.3380 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neola Medical AB worth?
The market values Neola Medical AB at about 54.1M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 0.4680; our models calculate a fair value of kr 0.1300 per share.
What do the bullish and bearish scenarios say about NEOLA?
Our models span a range for Neola Medical AB: cautious scenario kr 0.0900, base kr 0.1300, optimistic kr 0.1600 per share (as of Oct 3, 2026, price kr 0.4680). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neola Medical AB (NEOLA)?
Balance-sheet figures for Neola Medical AB (as of Oct 3, 2026): return on equity −14.2%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is NEOLA from its 52-week high?
Neola Medical AB trades at kr 0.4680, about 79% below its 52-week high of kr 2.18 and 3% above the low of kr 0.4540 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1300 is for.
Which stocks are comparable to Neola Medical AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neola Medical AB stock attractive at the current price?
The data as of Oct 3, 2026: price kr 0.4680, calculated fair value kr 0.1300 (−72%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEOLA calculated?
We run Neola Medical AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Neola Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neola Medical AB (NEOLA)?
The closing price on Oct 14, 2026 was kr 0.4680. Our model-based fair value is kr 0.1300, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neola Medical AB right now?
The price sits above even our optimistic bull case (kr 0.1600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Neola Medical AB

How large is the market capitalisation of Neola Medical AB (NEOLA)?
The market capitalisation of Neola Medical AB is 54.1M SEK (≈ $5.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Neola Medical AB (NEOLA)?
Earnings per share at Neola Medical AB are kr −0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Neola Medical AB (NEOLA)?
The return on equity (ROE) of Neola Medical AB is −14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neola Medical AB (NEOLA)?
On an EBIT basis the return on assets of Neola Medical AB is −14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neola Medical AB (NEOLA)?
The operating margin of Neola Medical AB is −111% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neola Medical AB (NEOLA)?
Revenue at Neola Medical AB is growing +52.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Neola Medical AB (NEOLA) generate?
The free cash flow of Neola Medical AB is −12.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neola Medical AB (NEOLA) hold?
Neola Medical AB holds more cash than debt, 16.1M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Neola Medical AB in the live analysis

One click puts Neola Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.